[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA41867A - Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) - Google Patents

Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)

Info

Publication number
MA41867A
MA41867A MA041867A MA41867A MA41867A MA 41867 A MA41867 A MA 41867A MA 041867 A MA041867 A MA 041867A MA 41867 A MA41867 A MA 41867A MA 41867 A MA41867 A MA 41867A
Authority
MA
Morocco
Prior art keywords
mucine
tim
antibodies
protein
cell immunoglobulin
Prior art date
Application number
MA041867A
Other languages
English (en)
Inventor
Silva Correia Jean Da
Marilyn Kehry
David J King
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of MA41867A publication Critical patent/MA41867A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA041867A 2015-04-01 2016-03-31 Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) MA41867A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562141353P 2015-04-01 2015-04-01

Publications (1)

Publication Number Publication Date
MA41867A true MA41867A (fr) 2018-02-06

Family

ID=57007695

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041867A MA41867A (fr) 2015-04-01 2016-03-31 Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)

Country Status (20)

Country Link
US (3) US10508149B2 (fr)
EP (2) EP4442712A2 (fr)
JP (1) JP6949717B2 (fr)
KR (1) KR102711906B1 (fr)
CN (2) CN114539409B (fr)
AU (1) AU2016242964C1 (fr)
BR (1) BR112017021040A2 (fr)
CA (1) CA2981520A1 (fr)
DK (1) DK3277321T3 (fr)
EA (1) EA201792184A1 (fr)
FI (1) FI3277321T3 (fr)
HK (1) HK1251150A1 (fr)
IL (2) IL283006B2 (fr)
LT (1) LT3277321T (fr)
MA (1) MA41867A (fr)
MX (1) MX2017012429A (fr)
PT (1) PT3277321T (fr)
SG (2) SG10201909173PA (fr)
WO (1) WO2016161270A1 (fr)
ZA (1) ZA201706740B (fr)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3812387A1 (fr) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Inhibiteurs de protéine kinase hétérocycliques
EP3049442A4 (fr) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Méthodes de traitement de cancers hématologiques
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3925622A1 (fr) 2014-09-13 2021-12-22 Novartis AG Polythérapies
SG11201707800QA (en) 2015-03-23 2017-10-30 Bayer Pharma AG Anti-ceacam6 antibodies and uses thereof
MA41867A (fr) * 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
NZ749355A (en) 2016-05-27 2023-04-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
CA3029813A1 (fr) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methodes et procedes pour favoriser la fonction des cellules immunitaires
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
CA3030765A1 (fr) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Anticorps anti-tim3 et leurs utilisations
JOP20190013A1 (ar) 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
MX2019005117A (es) 2016-11-01 2019-10-21 Anaptysbio Inc Anticuerpos dirigidos contra la muerte programada 1 (pd-1).
EP3689419A1 (fr) 2016-11-01 2020-08-05 AnaptysBio, Inc. Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CN108101989A (zh) * 2016-11-24 2018-06-01 复旦大学 针对人tim-3的全人源单域抗体及应用
WO2018106529A1 (fr) * 2016-12-08 2018-06-14 Eli Lilly And Company Anticorps anti-tim-3 pour combinaison avec des anticorps anti-pd-l1
JOP20190133A1 (ar) * 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
TWI665216B (zh) * 2016-12-29 2019-07-11 財團法人生物技術開發中心 抗人類tim-3抗體及其使用方法
TWI793094B (zh) * 2017-01-09 2023-02-21 美商提薩羅有限公司 用抗tim-3抗體治療癌症之方法
SG11201906192SA (en) 2017-01-09 2019-08-27 Tesaro Inc Methods of treating cancer with anti-pd-1 antibodies
EP3587452A4 (fr) 2017-02-27 2021-03-03 Jiangsu Hengrui Medicine Co., Ltd. Anticorps anti-tim-3, fragment de liaison à l'antigène de celui-ci, et utilisations médicales de celui-ci
MX2019012793A (es) 2017-04-27 2020-02-13 Tesaro Inc Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos.
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
AU2018270112A1 (en) 2017-05-18 2019-12-12 Tesaro, Inc. Combination therapies for treating cancer
WO2018229715A1 (fr) 2017-06-16 2018-12-20 Novartis Ag Compositions comprenant des anticorps anti-cd32b et procédés d'utilisation correspondants
KR20200021087A (ko) 2017-06-22 2020-02-27 노파르티스 아게 Cd73에 대한 항체 분자 및 이의 용도
TW201904993A (zh) 2017-06-22 2019-02-01 瑞士商諾華公司 IL-1β 結合抗體之用途
EP3642240A1 (fr) 2017-06-22 2020-04-29 Novartis AG Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
WO2018235056A1 (fr) 2017-06-22 2018-12-27 Novartis Ag Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer
US20200223924A1 (en) * 2017-06-27 2020-07-16 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
CA3070095A1 (fr) 2017-07-20 2019-01-24 Novartis Ag Regimes posologiques pour des anticorps anti-lag3 et leurs utilisations
EP4039274A1 (fr) 2017-07-28 2022-08-10 Phanes Therapeutics, Inc. Anticorps anti-tim-3 et leurs utilisations
WO2019046321A1 (fr) 2017-08-28 2019-03-07 Bristol-Myers Squibb Company Antagonistes de tim-3 pour le traitement et le diagnostic de cancers
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
AU2018341479B2 (en) 2017-09-26 2022-02-17 Tesaro, Inc. Niraparib formulations
WO2019067978A1 (fr) 2017-09-30 2019-04-04 Tesaro, Inc. Polythérapies pour le traitement du cancer
AU2018346688A1 (en) 2017-10-06 2020-04-23 Tesaro, Inc. Combination therapies and uses thereof
EP3700933A1 (fr) 2017-10-25 2020-09-02 Novartis AG Anticorps ciblant cd32b et leurs procédés d'utilisation
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
MX2020005651A (es) 2017-11-30 2020-10-28 Novartis Ag Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
WO2019136432A1 (fr) 2018-01-08 2019-07-11 Novartis Ag Arns renforçant le système immunitaire pour une combinaison avec une thérapie par récepteur d'antigène chimérique
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
MX2020009861A (es) 2018-03-23 2020-10-08 Bristol Myers Squibb Co Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
WO2019196911A1 (fr) 2018-04-12 2019-10-17 Nanjing Leads Biolabs Co., Ltd. Anticorps de liaison à tim-3 et son utilisation
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
US11505595B2 (en) * 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (fr) 2018-05-31 2019-12-05 Novartis Ag Molécules d'anticorps anti-cd73 et leurs utilisations
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
DK3820573T3 (da) 2018-07-10 2023-10-23 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (fr) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Procédé de traitement de tumeurs neuroendocrines
JP2021534093A (ja) 2018-08-20 2021-12-09 江蘇恒瑞医薬股▲ふん▼有限公司 腫瘍処置用医薬の製造におけるｔｉｍ−３抗体の使用
US20210261663A1 (en) 2018-08-28 2021-08-26 Jiangsu Hengrui Medicine Co., Ltd. Anti-tim3 antibody pharmaceutical composition and use thereof
TWI852940B (zh) 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
US11638730B2 (en) 2018-09-26 2023-05-02 Astellas Pharma Inc. Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
WO2020072796A1 (fr) 2018-10-03 2020-04-09 Tesaro, Inc. Formes cristallines d'une base libre de niraparib
WO2020072797A1 (fr) 2018-10-03 2020-04-09 Tesaro, Inc. Sels de niraparib
EP3890749A4 (fr) 2018-12-04 2022-08-03 Sumitomo Dainippon Pharma Oncology, Inc. Inhibiteurs de cdk9 et leurs polymorphes destinés à être utilisés en tant qu'agents pour le traitement du cancer
TW202039562A (zh) * 2018-12-12 2020-11-01 大陸商上海藥明生物技術有限公司 抗tim-3抗體及其用途
WO2020126808A1 (fr) 2018-12-19 2020-06-25 Bayer Aktiengesellschaft Combinaison pharmaceutique d'anticorps anti-ceacam6 et tim3
JP2022514315A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
TW202038959A (zh) 2018-12-20 2020-11-01 瑞士商諾華公司 Ｍｄｍ２抑制劑之新型給藥方案
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
EP3898675A1 (fr) 2018-12-21 2021-10-27 Novartis AG Utilisation d'anticorps de liaison à il-1 bêta dans le traitement ou la prévention du syndrome myélodysplasique
CA3118182A1 (fr) 2018-12-21 2020-06-25 Onxeo Nouvelles molecules d'acide nucleique conjuguees et leurs utilisations
WO2020128637A1 (fr) 2018-12-21 2020-06-25 Novartis Ag UTILISATION D'ANTICORPS DE LIAISON À IL-1β DANS LE TRAITEMENT D'UN CANCER MSI-H
BR112021012037A2 (pt) 2018-12-21 2021-11-03 Ose Immunotherapeutics Molécula anti-pd-1/il-7 bifuncional
US20220056123A1 (en) 2018-12-21 2022-02-24 Novartis Ag Use of il-1beta binding antibodies
WO2020167990A1 (fr) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprenant des inhibiteurs de protéine kinase hétérocycliques
WO2020165374A1 (fr) 2019-02-14 2020-08-20 Ose Immunotherapeutics Molécule bifonctionnelle comprenant il-15ra
AU2020222345B2 (en) 2019-02-15 2022-11-17 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021009764A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
AU2020245437A1 (en) 2019-03-22 2021-09-30 Sumitomo Pharma Oncology, Inc. Compositions comprising PKM2 modulators and methods of treatment using the same
WO2020192709A1 (fr) * 2019-03-27 2020-10-01 Wuxi Biologics (Shanghai) Co., Ltd. Nouveaux complexes polypeptidiques bispécifiques
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
JP2022534981A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよび組み合わせ治療
JP2022534967A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 多腫瘍遺伝子シグネチャーおよびその使用
WO2020257789A2 (fr) * 2019-06-21 2020-12-24 Single Cell Technology, Inc. Anticorps anti-tim-3
AU2020300619A1 (en) 2019-07-03 2022-01-27 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
BR112022001881A2 (pt) 2019-08-29 2022-06-21 Astellas Pharma Inc Vírus vaccinia oncolítico geneticamente manipulado e métodos de usos do mesmo
US20220306737A1 (en) 2019-09-16 2022-09-29 Novartis Ag Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
AU2020370832A1 (en) 2019-10-21 2022-05-19 Novartis Ag TIM-3 inhibitors and uses thereof
KR20220103947A (ko) 2019-10-21 2022-07-25 노파르티스 아게 베네토클락스 및 tim-3 억제제를 사용한 조합 요법
WO2021122866A1 (fr) 2019-12-17 2021-06-24 Ose Immunotherapeutics Molécules bifonctionnelles comprenant un variant de l'il-7
US20230059341A1 (en) 2019-12-18 2023-02-23 Tesaro, Inc. Biopharmaceutical compositions and related methods
TW202135858A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 抗ＴＧＦβ抗體和檢查點抑制劑用於治療增殖性疾病之用途
CN114980902A (zh) 2020-01-17 2022-08-30 诺华股份有限公司 用于治疗骨髓增生异常综合征或慢性粒单核细胞白血病的包含tim-3抑制剂和低甲基化药物的组合
CN115698075A (zh) * 2020-04-14 2023-02-03 葛兰素史密斯克莱知识产权发展有限公司 涉及抗icos和抗pd1抗体，任选地进一步涉及抗tim3抗体的癌症的组合治疗
TW202214857A (zh) 2020-06-19 2022-04-16 法商昂席歐公司 新型結合核酸分子及其用途
WO2021260528A1 (fr) 2020-06-23 2021-12-30 Novartis Ag Schéma posologique comprenant des dérivés de 3-(1-oxoisoindoline-2-yl) pipéridine-2,6-dione
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
MX2023002326A (es) 2020-08-31 2023-03-21 Bristol Myers Squibb Co Firma de localizacion celular e inmunoterapia.
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043558A1 (fr) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Méthode de traitement de cancers exprimant le psma
KR20230104651A (ko) 2020-11-06 2023-07-10 노파르티스 아게 Cd19 결합 분자 및 이의 용도
WO2022120179A1 (fr) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Signatures géniques multi-tumorales et leurs utilisations
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
MX2023007734A (es) 2020-12-28 2023-08-21 Bristol Myers Squibb Co Composiciones de anticuerpos y metodos de uso de las mismas.
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
WO2022148781A1 (fr) 2021-01-05 2022-07-14 Institut Curie Association d'activateurs de mcoln et d'inhibiteurs de point de contrôle immunitaire
TW202241508A (zh) 2021-01-29 2022-11-01 美商艾歐凡斯生物治療公司 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4320156A1 (fr) 2021-04-09 2024-02-14 Ose Immunotherapeutics Échafaudage pour molécules bifonctionnelles comprenant des domaines de liaison pd-1 ou cd28 et sirp
JP2024515263A (ja) 2021-04-09 2024-04-08 オーエスイー・イミュノセラピューティクス 改善された特性を有する二機能性分子のための新規足場構造
IL306100A (en) 2021-04-13 2023-11-01 Nuvalent Inc Amino-substituted heterocycles for the treatment of cancer with EGFR mutations
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
EP4396229A1 (fr) 2021-09-02 2024-07-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Anticorps anti-cecam6 à effets secondaires réduits
AU2022409713A1 (en) 2021-12-16 2024-06-20 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
KR20240130705A (ko) 2021-12-30 2024-08-29 네오이뮨텍, 인코퍼레이티드 Il-7 단백질 및 vegf 길항제의 조합으로 종양을 치료하는 방법
WO2023147488A1 (fr) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Compositions et procédés de lymphocytes infiltrant les tumeurs associés à la cytokine
CN118871451A (zh) 2022-03-18 2024-10-29 百时美施贵宝公司 分离多肽的方法
WO2023214325A1 (fr) 2022-05-05 2023-11-09 Novartis Ag Dérivés de pyrazolopyrimidine et leurs utilisations en tant qu'inhibiteurs de tet2
WO2023235847A1 (fr) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Compositions d'anticorps et leurs procédés d'utilisation
WO2024003360A1 (fr) 2022-07-01 2024-01-04 Institut Curie Biomarqueurs et leurs utilisations pour le traitement du neuroblastome
WO2024028386A1 (fr) 2022-08-02 2024-02-08 Ose Immunotherapeutics Molécule multifonctionnelle dirigée contre cd28
WO2024102722A1 (fr) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Procédés de traitement d'une tumeur avec un promoteur mgmt non méthylé
WO2024163477A1 (fr) 2023-01-31 2024-08-08 University Of Rochester Thérapie de blocage de point de contrôle immunitaire pour le traitement d'infections par staphylococcus aureus
WO2024200823A1 (fr) 2023-03-30 2024-10-03 Ose Immunotherapeutics Nanoparticule à base de lipide ciblant des cellules immunitaires activées pour l'expression d'une molécule d'amélioration de cellule immunitaire et son utilisation
WO2024200826A1 (fr) 2023-03-30 2024-10-03 Ose Immunotherapeutics Nanoparticule à base de lipides ciblée au niveau de cellules immunitaires activées pour l'expression d'une molécule inhibitrice de cellules immunitaires et son utilisation
WO2024211551A1 (fr) 2023-04-06 2024-10-10 Glaxosmithkline Intellectual Property (No.4) Limited Méthodes de traitement et de surveillance du cancer

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
DE69128037T2 (de) 1990-11-13 1998-05-07 Immunex Corp., Seattle, Wash. Bifunktionelle wählbare fusionsgene
JPH09500783A (ja) 1993-05-21 1997-01-28 ターゲッティッド ジェネティクス コーポレイション シトシンデアミナーゼ（ｃｄ）遺伝子に基づく二機能性選択融合遺伝子
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US6843987B2 (en) 2000-02-02 2005-01-18 Schering Corporation Mammalian cytokines; receptors; related reagents and methods
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US20030103985A1 (en) * 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
WO2003048731A2 (fr) 2001-12-03 2003-06-12 Abgenix, Inc. Categorisation d'anticorps reposant sur des caracteristiques de liaison
EP4091631A1 (fr) * 2002-01-30 2022-11-23 The Brigham and Women's Hospital, Inc. Molécule de liaison à tim-3 pour utilisation dans le traitement d'une maladie
AU2003262386A1 (en) * 2002-04-17 2003-11-03 Michael R. Blaese Short fragment homologous replacement to provide bse resistant cattle
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
WO2006121168A1 (fr) 2005-05-09 2006-11-16 Ono Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d’autres immunotherapies
US7824681B2 (en) 2005-08-16 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services Human monoclonal antibodies that specifically bind IGF-II
WO2008011348A2 (fr) 2006-07-14 2008-01-24 Ac Immune S.A. Anticorps humanisé
MX341064B (es) 2006-09-08 2016-08-05 Amgen Inc * Variantes de la familia il-1.
PL2109608T3 (pl) 2007-01-10 2011-08-31 Msd Italia Srl Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
NZ579010A (en) 2007-02-20 2012-03-30 Anaptysbio Inc Somatic hypermutation systems
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
ES2548131T3 (es) 2008-01-08 2015-10-14 Merck Sharp & Dohme Limited Sales farmacéuticamente aceptables de 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida
WO2009114335A2 (fr) 2008-03-12 2009-09-17 Merck & Co., Inc. Protéines de liaison avec pd-1
WO2009129247A2 (fr) 2008-04-14 2009-10-22 Innovative Targeting Solutions Inc. Creation de diversite de sequences dans des immunoglobulines
KR20110048536A (ko) 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도
TWI629483B (zh) * 2010-06-11 2018-07-11 協和醱酵麒麟有限公司 anti-TIM-3 antibody
US9163087B2 (en) * 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
WO2013006490A2 (fr) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Anticorps se liant spécifiquement à tim3
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP2748197A2 (fr) * 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Anticorps bispécifiques à fc en tandem
CN107007833B (zh) 2011-11-16 2020-12-11 勃林格殷格翰国际有限公司 抗il-36r抗体
CN102492038B (zh) * 2011-12-09 2014-05-28 中国人民解放军军事医学科学院基础医学研究所 抗人Tim-3的中和性单克隆抗体L3D及其用途
PL2797952T3 (pl) 2011-12-28 2019-09-30 Immunoqure Ag Sposób zapewnienia autoprzeciwciał monoklonalnych o pożądanej specyficzności
KR101704893B1 (ko) 2012-06-15 2017-02-08 화이자 인코포레이티드 Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
WO2014165115A1 (fr) 2013-03-12 2014-10-09 Decimmune Therapeutics, Inc. Anticorps humanisés anti-n2
CN105209497B (zh) 2013-03-15 2021-09-07 诺和诺德股份有限公司 能够特异性结合组织因子途径抑制物上的两个表位的抗体
MX2015015037A (es) * 2013-05-02 2016-07-08 Anaptysbio Inc Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1).
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
ME03558B (fr) 2014-03-14 2020-07-20 Novartis Ag Molécules d'anticorps anti-lag-3 et leurs utilisations
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
CN107001475B (zh) 2014-11-06 2021-01-29 豪夫迈·罗氏有限公司 抗tim3抗体及使用方法
GB201421430D0 (en) 2014-12-02 2015-01-14 Medimmune Llc Antibodies to Adam17 and uses thereof
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
DK3303386T3 (da) 2015-06-05 2024-10-28 Genentech Inc Anti-Tau-antistoffer og fremgangsmåder til anvendlelse
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
UA126896C2 (uk) 2015-11-03 2023-02-22 Янссен Байотек, Інк. Антитіло, що специфічно зв’язується з pd-1, і спосіб його застосування
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
EP3689419A1 (fr) 2016-11-01 2020-08-05 AnaptysBio, Inc. Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
TWI793094B (zh) 2017-01-09 2023-02-21 美商提薩羅有限公司 用抗tim-3抗體治療癌症之方法
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación

Also Published As

Publication number Publication date
US20180127500A1 (en) 2018-05-10
EP3277321A1 (fr) 2018-02-07
JP6949717B2 (ja) 2021-10-13
JP2018512138A (ja) 2018-05-17
HK1251150A1 (zh) 2019-01-25
US11352427B2 (en) 2022-06-07
AU2016242964B2 (en) 2022-01-13
IL254559B1 (en) 2023-03-01
US10508149B2 (en) 2019-12-17
ZA201706740B (en) 2024-07-31
EP3277321A4 (fr) 2018-12-12
IL283006A (en) 2021-06-30
CN107847589B (zh) 2022-03-29
LT3277321T (lt) 2024-10-25
US20220363759A1 (en) 2022-11-17
CN114539409B (zh) 2024-09-17
MX2017012429A (es) 2018-01-26
EP3277321B1 (fr) 2024-08-14
SG11201707705UA (en) 2017-10-30
PT3277321T (pt) 2024-09-17
SG10201909173PA (en) 2019-11-28
WO2016161270A1 (fr) 2016-10-06
IL254559A (en) 2019-02-10
AU2016242964C1 (en) 2022-06-09
IL283006B2 (en) 2023-10-01
CA2981520A1 (fr) 2016-10-06
DK3277321T3 (da) 2024-09-02
US20200148770A1 (en) 2020-05-14
EP4442712A2 (fr) 2024-10-09
AU2016242964A1 (en) 2017-11-09
KR102711906B1 (ko) 2024-09-27
EA201792184A1 (ru) 2018-04-30
IL254559B2 (en) 2023-07-01
CN107847589A (zh) 2018-03-27
CN114539409A (zh) 2022-05-27
BR112017021040A2 (pt) 2018-07-24
KR20170133458A (ko) 2017-12-05
FI3277321T3 (fi) 2024-10-31
IL283006B1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
MA41867A (fr) Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
MA46113A (fr) Anticorps dirigés contre l'immunoglobuline de lymphocyte t et la protéine 3 de mucine (tim-3)
EP3621642A4 (fr) Anticorps monoclonaux humains contre lag3 et leurs utilisations
MA43955A (fr) Anticorps anti-bcma et anti-cd3 bispécifiques de format bite
ZA201900059B (en) Anti-b7-h3 antibodies and antibody drug conjugates
MA43859A (fr) Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
SG11202011270QA (en) Anti-cd3 antibodies and uses thereof
SG11202001368SA (en) Antigen-binding proteins tatrgeting shared antigens
EP3459597A4 (fr) Anticorps à domaine unique anti-ctla4 et protéine dérivée de celui-ci
DK3515487T3 (da) Bispecifikke anti-MUC16-CD3-antistoffer og anti-MUC16-lægemiddelkonjugater
SG11202012671QA (en) Anti-pd-1 antibodies and uses thereof
MA42446A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA55043A (fr) Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20
DK3710484T5 (da) Ctla-4-bindende antistoffer og anvendelser deraf
DK3504241T3 (da) Anti-cd3-antistofformuleringer
EP3181587A4 (fr) Anticorps monoclonal anti-il-17 humain et son utilisation
DK3380122T3 (da) Anti-5t4 antistoffer og antistoflægemiddel konjugater
MA43738A (fr) Anticorps anti-tnfalpha et leurs fragments fonctionnels
MA49250A (fr) Nouveaux anticorps anti-cd3
IL283180A (en) Anti-PD-1 antibodies and their uses
MA43717A (fr) Anticorps anti-tnf et fragments fonctionnels de ceux-ci
IL276675A (en) Anti-PD-1 antibodies and uses thereof
MA44777A (fr) Anticorps humanisés anti-basigine et leur utilisation
EP3464355A4 (fr) Anticorps monoclonal dirigé contre dsg2 et son utilisation
MA43715A (fr) Anticorps anti-tnf et fragments fonctionnels correspondants